About: Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Sector: Healthcare
Industry: Biotechnology
Latest price: $39.81 (-2.53%)
ELVN NASDAQ Enliven Therapeutics Inc.
Enliven Therapeutics Inc. share price
ELVN price activity
Last Price
$39.810
Change (24hr)
-1.04 USD (-2.53%)
Volume
242.71K
Volume (4w avg)
-
Open
$40.86
Day Range
$39.81 - $40.86
Previous Close
$40.84
Last Trade
13 Oct, 5:33 pm GMT+0
Delayed
13 Oct, 5:33 pm GMT+0
ELVN price performance
Delayed
13 Oct, 5:33 pm GMT+0
ELVN Market Signals